{"id":"bypassing-agents","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4298067","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents work by circumventing the need for functional factor VIII or factor IX, which are blocked by inhibitory antibodies in some hemophilia patients. They directly activate factor X or provide alternative pathways to generate thrombin, thereby restoring hemostatic capacity and preventing or treating bleeding episodes.","oneSentence":"Bypassing agents are coagulation factors that activate the coagulation cascade downstream of factors VIII and IX to restore thrombin generation in patients with inhibitors to these factors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:32.292Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A with factor VIII inhibitors"},{"name":"Hemophilia B with factor IX inhibitors"},{"name":"Bleeding episodes in inhibitor patients"}]},"trialDetails":[{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT04083781","phase":"PHASE3","title":"Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-10-21","conditions":"Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":134},{"nctId":"NCT06998524","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-27","conditions":"Von Willebrand Disease, Type 3","enrollment":75},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT05345197","phase":"PHASE2","title":"Emicizumab in Patients With Acquired Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2022-08-31","conditions":"Acquired Hemophilia A","enrollment":51},{"nctId":"NCT06145373","phase":"PHASE4","title":"A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-03-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT02453542","phase":"","title":"Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2015-03-01","conditions":"Hemophilia","enrollment":20},{"nctId":"NCT07009730","phase":"","title":"Clinical Outcomes Between Pulsatile and Non-Pulsatile Flow During Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Tribhuvan University Teaching Hospital, Institute Of Medicine.","startDate":"2019-07-23","conditions":"Cardiac Surgery, Cardiac Surgery Requiring Cardiopulmonary Bypass","enrollment":80},{"nctId":"NCT03619863","phase":"","title":"ATHN 7: Hemophilia Natural History Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2018-10-24","conditions":"Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor","enrollment":395},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":"Hemophilia A","enrollment":12},{"nctId":"NCT03417102","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-02-14","conditions":"Hemophilia A, Hemophilia B","enrollment":60},{"nctId":"NCT02622321","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-18","conditions":"Hemophilia A","enrollment":113},{"nctId":"NCT02476942","phase":"","title":"A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-26","conditions":"Hemophilia A","enrollment":221},{"nctId":"NCT00710619","phase":"","title":"Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":52},{"nctId":"NCT01800435","phase":"PHASE4","title":"A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2011-10","conditions":"Hereditary Factor VIII Deficiency Disease With Inhibitor","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":505,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bypassing Agents","genericName":"Bypassing Agents","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bypassing agents are coagulation factors that activate the coagulation cascade downstream of factors VIII and IX to restore thrombin generation in patients with inhibitors to these factors. Used for Hemophilia A with factor VIII inhibitors, Hemophilia B with factor IX inhibitors, Bleeding episodes in inhibitor patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}